Rhythm Pharmaceuticals' Imcivree Succeeds in Phase 3 for Hypothalamic Obesity, Contrary to Failure Reports, with PDUFA Date Approaching

on

Rhythm Pharmaceuticals announced positive topline results from the Phase 3 TRANSCEND trial of Imcivree (setmelanotide) in acquired hypothalamic obesity, showing a 16.5% mean BMI reduction from baseline versus a 3.3% increase on placebo12.

Additional data confirmed an 18.8% placebo-adjusted BMI reduction across 142 patients at 52 weeks, with the FDA PDUFA goal date of March 20, 2026 for the sNDA3.

83% of Imcivree-treated patients achieved ≥5% BMI reduction; significant improvements in hunger scores were also observed23.

No new safety signals reported; Imcivree is already approved for rare genetic obesity conditions like POMC, PCSK1, LEPR deficiencies and Bardet-Biedl syndrome12.

Company plans NDA submission to FDA and EMA by Q3 2025; analysts view results as outstanding, derisking approval in this difficult-to-treat population1.

Sources:

1. https://www.biospace.com/drug-development/rhythm-drug-leads-to-reduced-bmi-in-rare-obesity-indication

2. https://www.clinicaltrialsarena.com/news/rhythm-seeks-market-expansion-imcivree-phase-iii-victory/

3. https://www.globenewswire.com/news-release/2026/03/01/3246959/0/en/rhythm-pharmaceuticals-announces-additional-positive-data-from-phase-3-transcend-trial-of-setmelanotide-in-patients-with-acquired-hypothalamic-obesity.html